WHERE ARE YOU?

Concept Pre-Sub Submission prep Newly cleared Raising Exit Postmarket & security

THE TAPE

FDA makes the Draeger VentStar Resus Neo hose removal a Class I recall Control Bionics wins a Class I CE mark for the NeuroStrip muscle sensor Medicare starts paying for Carlsmed Aprevo lumbar fusion under three new codes ABK Biomedical breaks ground on a Missouri plant for its Y90 microspheres Boston Scientific releases the last $8M from Elutia's BioEnvelope sale BlueWind gets a Category I CPT code for subfascial tibial neuromodulation Emboline runs its first US commercial Emboliner cases at Columbia SedMed raises $4M for a toilet lift that runs without power CDRH plans 11 final guidances in FY2027 and puts AI lifecycle management first FDA makes the Draeger VentStar Resus Neo hose removal a Class I recall Control Bionics wins a Class I CE mark for the NeuroStrip muscle sensor Medicare starts paying for Carlsmed Aprevo lumbar fusion under three new codes ABK Biomedical breaks ground on a Missouri plant for its Y90 microspheres Boston Scientific releases the last $8M from Elutia's BioEnvelope sale BlueWind gets a Category I CPT code for subfascial tibial neuromodulation Emboline runs its first US commercial Emboliner cases at Columbia SedMed raises $4M for a toilet lift that runs without power CDRH plans 11 final guidances in FY2027 and puts AI lifecycle management first

Financing

Boston Scientific releases the last $8M from Elutia's BioEnvelope sale

MedDevice Startups Staff · 5 days ago · 2 min read · Via Elutia (BioSpace)

Elutia has collected the full $8M that Boston Scientific held back from the October 2025 sale of its BioEnvelope business. The $88M deal carried a one year indemnity holdback. No claims were filed, and the escrow released on October 1.

Elutia (Nasdaq: ELUT) says the money carries it through the first full year of the NXT-41x launch and into 2029 without an equity offering. NXT-41x is its next antibiotic-eluting surgical matrix, with FDA clearance expected in the first half of 2027. Two earlier moves did similar work this year: an Avenue Capital loan facility on August 11 and the SimpliDerm divestiture on August 17.

Three non-dilutive sources inside two months is the profile of a company that would rather sell assets than price a round at this share price. The runway math assumes NXT-41x clears on schedule, which makes the submission timeline the number to watch rather than the cash balance.

Questions & Answers

How much did Boston Scientific pay Elutia in October 2026?

Boston Scientific released $8M of escrow to Elutia on October 1, 2026. The money was the indemnity holdback from Boston Scientific's $88M purchase of Elutia's BioEnvelope business in October 2025.

Is Elutia funded without raising equity?

Elutia says the $8M escrow release leaves it funded through the first full year of its NXT-41x launch and into 2029, with no equity offering required. It also closed an Avenue Capital loan facility and the SimpliDerm divestiture in August 2026.

When does Elutia expect FDA clearance for NXT-41x?

Elutia expects FDA clearance of NXT-41x, its next-generation antibiotic-eluting surgical matrix, in the first half of 2027.

← Back to Fundraising